美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.67

-0.4558-1.30%

成交量：1.86萬

成交額：64.64萬

市值：9,638.26萬

市盈率：- -

高：35.13

開：35.13

低：34.63

收：35.13

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：1.40

換手率：0.67%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

羅氏（RHHBY）宣佈旗下血液癌雙抗Lunsumio三期臨床試驗達到主要終點

聯儲局加息靴子落地，A股縮量調整，糧食、創新藥概念走強| 華寶基金3A日報（2026.9.17）

全球首個AI原創新藥Ⅲ期臨床給藥：不僅逆轉肺纖維化，更展現「抗衰老」信號

997億美元BD交易背後：CRO熬過寒冬，迎來供需反轉時刻

ETF風向標|創新藥、農業股全天強勢，糧食ETF、港股通醫療ETF漲2%，中證1000ETF、中證500ETF資金淨流入居前

A股收評：滬指窄幅震盪收跌0.41%，糧食概念、汽車整車、創新藥板塊漲幅居前

諾和諾德、禮來、字節系落子AI製藥，A股創新藥、CRO板塊嗨了

华尔街见闻

午評：創業板指衝高回落跌0.12%，糧食概念、汽車整車、創新藥板塊漲幅居前

突發異動！300434，3分鐘直線20%漲停！創新藥，集體爆發！

國信證券：醫藥中報景氣度提升繼續推薦創新藥及產業鏈

創新藥概念走強金斯瑞生物科技（01548）升逾15% 機構指醫藥行業基本面持續改善

創新藥、CRO概念漲勢擴大近岸蛋白等多股漲停

創新藥板塊短線走高，金石亞藥觸及20cm漲停

三重動力支撐創新藥企「強者更強」

通用電氣可再生能源表示，有意開展更多併購交易，且幾乎可以肯定交易將圍繞自身核心業務展開。

石藥集團SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心啓動

吉利德科學擴大六項免許可費自願授權協議，力推每年一次HIV預防藥Lenacapavir

上海萊士(002252.SZ)：「SR604注射液」進入Ⅲ期臨床試驗

上海萊士：SR604注射液進入Ⅲ期臨床試驗

Sling Therapeutics 籌集 1.23 億美元，用於推進甲狀腺相關眼病藥物的研發

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IBBQ/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.67,"timestamp":1789752061778,"preClose":35.1258,"halted":0,"volume":18606,"delay":0,"changeRate":-0.012976216911785538,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"交易中","change":-0.4558,"latestTime":"09-18 13:21:45 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":646429.9325400001,"amplitude":0.014246,"askPrice":34.68,"askSize":3400,"bidPrice":34.64,"bidSize":700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":34.34966,"aum":95492089.14966,"dividendRate":0.00741,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.14,"preClose":35.1258,"latestTime":"19:58 EDT","volume":117,"amount":4061.8054,"timestamp":1789689522745,"change":0.0142,"changeRate":0.000404,"amplitude":0},"volumeRatio":1.398319,"impliedVol":0.1125,"impliedVolPercentile":0.4821},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.398319,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.67,"committee":-0.658537,"eps":0,"divideRate":0.00741,"volume":18606,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668619429","title":"羅氏（RHHBY）宣佈旗下血液癌雙抗Lunsumio三期臨床試驗達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2668619429","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668619429?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 19:29","pubTimestamp":1789644589,"startTime":"0","endTime":"0","summary":"金吾财讯 | 制药巨头罗氏 旗下基因泰克宣布，其CD20/CD3双特异性抗体Lunsumio联合来那度胺的组合疗法，在治疗复发或难治性滤泡性淋巴瘤的后期III期CELESTIMO临床试验中达到主要终点。据悉，Lunsumio此前已基于加速批准/有条件上市许可在日本及欧美上市，用于三线及以上滤泡性淋巴瘤患者。罗氏计划在即将举行的学术会议上公布具体数据，并向全球卫生监管机构提交上市申请，进一步巩固其在血液肿瘤治疗领域的领先地位。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306169","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","HRTS","BK4007","IBBQ","RHHBY","MDTX","PSYK","IBBJ","BMED","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668969226","title":"聯儲局加息靴子落地，A股縮量調整，糧食、創新藥概念走強| 華寶基金3A日報（2026.9.17）","url":"https://stock-news.laohu8.com/highlight/detail?id=2668969226","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668969226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 19:02","pubTimestamp":1789642920,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-17/doc-iniscvfv3943978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159982","03188","06978","159992","IBBQ","MEDX","PTMC","399300","03130","02846","82846","EQRR","BK1147","BK1161","LNGR","07233","02827","83130","159073","83188","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668796951","title":"全球首個AI原創新藥Ⅲ期臨床給藥：不僅逆轉肺纖維化，更展現「抗衰老」信號","url":"https://stock-news.laohu8.com/highlight/detail?id=2668796951","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668796951?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 18:47","pubTimestamp":1789642076,"startTime":"0","endTime":"0","summary":"记者从AI制药企业英硅智能获悉，9月上旬，北京协和医院、上海市肺科医院先后完成了一例特殊的给药——全球首个由人工智能完成靶点发现与分子设计的治疗特发性肺纤维化候选药物Rentosertib，正式进入Ⅲ期临床试验首例患者给药阶段。这不是一次普通的临床推进。它意味着，AI制药第一次真正站到了新药上市前的最后一道关卡面前。而这款药的潜力，可能不止于治疗肺纤维化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609173877435857.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609173877435857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AIPO","159992","ARTY","CHAT","IBBQ","06978","BK1574","LNGR","MEDX","VTHR","AGIX","QTOC","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668496689","title":"997億美元BD交易背後：CRO熬過寒冬，迎來供需反轉時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2668496689","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668496689?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 18:10","pubTimestamp":1789639801,"startTime":"0","endTime":"0","summary":"创新药出海全面爆发国产创新药出海持续提速，成为本轮CRO行业回暖的核心驱动力。渤海证券研报显示，2026年上半年我国创新药对外授权交易数量突破100笔，交易总金额达到997亿美元，交易规模创下历年同期新高，延续了2025年的高增长态势。临床CRO龙头泰格医药深度绑定国内创新药BD出海浪潮，国内多中心临床试验需求释放，作为临床CRO标杆企业，充分受益本土创新药研发回暖。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/17/20260917555605.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/17/20260917555605.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260917/32373302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0046","301047","688137","06978","BK0028","LNGR","BK0077","BK1161","BK0216","000504","300434","BK0086","BK0042","BK0239","BK1574","300683","IBBQ","BK0282","600721","301520","MEDX","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668686099","title":"ETF風向標|創新藥、農業股全天強勢，糧食ETF、港股通醫療ETF漲2%，中證1000ETF、中證500ETF資金淨流入居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2668686099","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668686099?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 17:09","pubTimestamp":1789636187,"startTime":"0","endTime":"0","summary":"8张图速览","market":"hk","thumbnail":"https://img3.gelonghui.com/687f4-93465223-96ba-4173-acad-3ac89a0081e3.jpg?guru_height=787&guru_width=1280&guru_size=119553","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/687f4-93465223-96ba-4173-acad-3ac89a0081e3.jpg?guru_height=787&guru_width=1280&guru_size=119553"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6701725","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159967","82843","KWEB","000688.SH","589190","512510","FXP","02823","000852.SH","ASHR","ASHS","IBBQ","512880","FLCH","159845","399006","510880","513350","510500","CHAU","06978","399001","CWEB","LNGR","588710","159992","FLHK","513620","FDN","XPP","000001.SH","159915","YANG","YXI","510300","588990","159982","159587","159698","512710","159041","515890","000300.SH","YINN","000905.SH","399852","399905","82823","MEDX","159828"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668543639","title":"A股收評：滬指窄幅震盪收跌0.41%，糧食概念、汽車整車、創新藥板塊漲幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2668543639","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668543639?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 15:01","pubTimestamp":1789628482,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668518799","title":"諾和諾德、禮來、字節系落子AI製藥，A股創新藥、CRO板塊嗨了","url":"https://stock-news.laohu8.com/highlight/detail?id=2668518799","media":"华尔街见闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668518799?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 14:26","pubTimestamp":1789626360,"startTime":"0","endTime":"0","summary":"诺和诺德与Anthropic达成AI合作，金斯瑞携手礼来TuneLab平台提供湿实验验证，字节拆分的Anew Labs亦获2.9亿美元融资。多重重磅合作与融资密集落地，显现AI制药协作热潮，带动A股创新药、CRO板块大涨。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3781972","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","07233","01477","03188","159982","VTHR","03130","BK1161","BGIA","82846","02846","MEDX","83130","LNGR","ARTY","BK1191","AIPO","399300","83188","BK1147","CHAT","BK1574","06978","QTOC","AGIX","159992","02827"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668195332","title":"午評：創業板指衝高回落跌0.12%，糧食概念、汽車整車、創新藥板塊漲幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2668195332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668195332?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 11:34","pubTimestamp":1789616053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668047930","title":"突發異動！300434，3分鐘直線20%漲停！創新藥，集體爆發！","url":"https://stock-news.laohu8.com/highlight/detail?id=2668047930","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668047930?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 10:32","pubTimestamp":1789612320,"startTime":"0","endTime":"0","summary":"9月17日，A股主要指数集体低开。盘面上，视频媒体、房产租赁经纪、玻纤制造等板块涨幅居前，MLCC概念、贵金属、风电设备、油气开采等板块跌幅居前。创新药概念股走强创新药板块短线走高，金 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260917/c680001119.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260917/c680001119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","BK1574","159992","MEDX","BK0028","BK0077","300434","IBBQ","BK0239","06978","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668958679","title":"國信證券：醫藥中報景氣度提升 繼續推薦創新藥及產業鏈","url":"https://stock-news.laohu8.com/highlight/detail?id=2668958679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668958679?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 10:29","pubTimestamp":1789612194,"startTime":"0","endTime":"0","summary":"国信证券主要观点如下：医药行业中报景气度提升2026年上半年A股医药行业上市公司实现营业收入11942.1亿元，同比增长2.6%;归母净利润1049.6亿元，同比增长10.8%，利润增速明显快于收入端。整体来看，2026年上半年医药行业基本面持续改善，盈利修复趋势进一步确认，创新药及CXO等高景气方向表现突出。中国创新药在海外的临床开发取得进展，即将进入在全球的商业化阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK0188","BK1574","IBBQ","BK1161","BK0028","06978","002736","BK0183","159938","BK1515","159992","MEDX","LNGR","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668930750","title":"創新藥概念走強 金斯瑞生物科技（01548）升逾15% 機構指醫藥行業基本面持續改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2668930750","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668930750?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 10:29","pubTimestamp":1789612152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念走强，截止发稿，金斯瑞生物科技 涨15.29%，维亚生物涨6.32%，凯莱英涨6.08%，泰格医药涨4.86%，昭衍新药涨4.96%。消息面上，国信证券表示，2026年上半年医药行业收入保持稳健增长，利润端实现双位数增长，26Q2盈利增速进一步提升，创新药及产业链维持较高景气。整体来看，2026年上半年医药行业基本面持续改善，盈利修复趋势进一步确认，创新药及CXO等高景气方向表现突出。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06127","BK1141","06978","BK1576","01548","BK1191","159992","06821","BK1574","MEDX","HK0000320223.HKD","IBBQ","03347","HK0000306701.USD","HK0000320264.USD","HK0000306685.HKD","LNGR","01873","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668470930","title":"創新藥、CRO概念漲勢擴大 近岸蛋白等多股漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2668470930","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668470930?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 10:26","pubTimestamp":1789611962,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668937166","title":"創新藥板塊短線走高，金石亞藥觸及20cm漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2668937166","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668937166?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 09:35","pubTimestamp":1789608958,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668987804","title":"三重動力支撐創新藥企「強者更強」","url":"https://stock-news.laohu8.com/highlight/detail?id=2668987804","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668987804?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 00:01","pubTimestamp":1789574460,"startTime":"0","endTime":"0","summary":"今年以来，创新药行业分化愈发明显。招商证券统计显示，91家A/H股创新药公司中，2026年上半年共有44家实现盈利，其中盈利额前五的公司占全部盈利公司利润总额的48%。中国创新药跨境BD（商务拓展）同样呈现集中趋势。据动脉智库数据，2026年上半年，中国创新药对外BD的潜在总额达1100亿美元，其中，交易金额体量排名前十的项目的总金额为739.14亿美元，占比在六成以上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609173876437951.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609173876437951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1574","LNGR","06978","IBBQ","MEDX","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667984205","title":"通用電氣可再生能源表示，有意開展更多併購交易，且幾乎可以肯定交易將圍繞自身核心業務展開。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667984205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667984205?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 23:38","pubTimestamp":1789573119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IYH","PEVC","SDGS","DFMC","SOLR","IEFN","VCLN","RFG","SMOG","BK4588","RSPH","RNRG","FFSM","AAUM","MNA","TMED","PWER","PRVT","GTPE","MMID","HEAT","ACTV","PSP","PBW","IBBQ","VXF","TBXU","ACES","XLFI","CANC","PBPH","UYG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667989312","title":"石藥集團SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2667989312","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667989312?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 21:55","pubTimestamp":1789566903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","PSYK","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164691459","title":"吉利德科學擴大六項免許可費自願授權協議，力推每年一次HIV預防藥Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=1164691459","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164691459?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 20:31","pubTimestamp":1789561872,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，扩大其六项免许可费的自愿授权协议，覆盖其每年仅需注射一次的HIV预防药物Lenacapavir。此举旨在拓宽药物可及性，助力全球抗击艾滋病疫情。通过这一系列协议，吉利德希望加快该长效预防方案在中低收入国家的推广，以应对持续存在的公共卫生挑战。该举措不仅彰显了公司在全球健康公平方面的承诺，也为实现2030年终结艾滋病流行的目标注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0289739699.SGD","GILD","BK4578","BIB","LU0889565916.HKD","IE00B7SZLL34.SGD","BK4550","LU1430594728.SGD","LU1674673428.USD","LU2089984988.USD","LU0823416689.USD","LU2324357040.USD","LU1023059063.AUD","LU1585245621.USD","TMED","LU1037948541.HKD","LU1066053197.SGD","BK4139","MEDI","SG9999015986.USD","IE00B19Z3B42.SGD","LU1934455277.USD","LU0965509101.SGD","LU2087621335.USD","BK4568","IBBQ","IE00BSNM7G36.USD","LU2468319806.SGD","SG9999015978.USD","LU0965509010.AUD","LU1057294990.SGD","LU0109394709.USD","IE0002270589.USD","BK4532","LU0859254822.USD","LU1066051498.USD","BK4585","BMED","LU0861579265.USD","LU2357627491.SGD","SG9999015945.SGD","LU0965509283.SGD","LU0234570918.USD","IE00B19Z3581.USD","BBH","LU0965508806.USD","LU0320765992.SGD","IBB","LU1571399168.USD","IE00BKVL7J92.USD","LU1778281490.HKD","LU2112291526.USD","IE00B3T34201.USD","LU1934455194.USD","BK4566","LU0122379950.USD","LU1674673691.USD","LU1839511570.USD","TBXU","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU1037948897.HKD","SG9999015952.SGD","BK4583","BK4588","LU0058720904.USD","LU1061106388.HKD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988673","title":"上海萊士(002252.SZ)：「SR604注射液」進入Ⅲ期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988673","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667988673?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:56","pubTimestamp":1789559791,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海莱士 发布公告，公司在研产品“SR604注射液”于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了“血友病A/B患者出血发作的预防治疗”Ⅲ期临床试验登记信息，试验名称：评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性和安全性的单臂、多中心Ⅲ期临床试验试验目的：评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","MDTX","002252","BK0196","BK0188","BK0046","BK0028","BK0239","IBBJ","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667498863","title":"上海萊士：SR604注射液進入Ⅲ期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667498863","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667498863?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:51","pubTimestamp":1789559491,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","BMED","PSYK","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667074086","title":"Sling Therapeutics 籌集 1.23 億美元，用於推進甲狀腺相關眼病藥物的研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2667074086","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667074086?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556485,"startTime":"0","endTime":"0","summary":"Sling Therapeutics 筹集 1.23 亿美元，用于推进甲状腺相关眼病药物的研发Kunal Das/Siddhi Mahatole路透9月16日-药物研发公司Sling Therapeutics周三表示，已筹集1.23亿美元，用于推进其用于治疗甲状腺眼病的实验性口服药物的后期临床试验。该疾病会导致眼周发炎和肿胀，进而可能引发眼球突出和视力丧失。作为此次融资协议的一部分，Sling还任命了Forbion的Regina Salvat和Sectoral Asset Management的Franois Beaubien加入其董事会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4T4580NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4599","IE00B4R5TH58.HKD","LU2242646821.SGD","PJP","BK4566","LU1057294990.SGD","TBXU","LU1061106388.HKD","LU0122379950.USD","LU0058720904.USD","BK4588","LU0109394709.USD","LU0289739699.SGD","PBE","IE00BJT1NW94.SGD","BK4139","LU2112291526.USD","BBH","BK4585","IBB","IE00BFTCPJ56.SGD","BK4533","IE00B2B36J28.USD","BK4581","LU0320765992.SGD","IE0002141913.USD","LU1571399168.USD","LU1983299246.USD","BIB","SG9999001440.SGD","AMGN","LU2089984988.USD","LU0889565916.HKD","BK4534","LU2242652126.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","IBBQ","LU0868494617.USD","IE0009355771.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":2,"totalSize":219,"code":"91000000","status":"200"}]}}